Abstracts tagged "fibrosis and systemic sclerosis"

Abstract Number: 113 • 2018 ACR/ARHP Annual Meeting
Epigenetic Changes in Dermal Fibroblasts By Inhibition of DOT1L Affect Cell Proliferation and Cell Cycle, but Have No Direct Effects on Collagen Deposition in in Vitro and In Vivo models of Fibrosis
Nathalie Berghen^1,2, Jonathan Cremer³, Ellen de Langhe^1,2 and Rik Lories^1,2, ¹Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Belgium, ²Rheumatology, UZ Leuven, Leuven, Belgium, ³Translational Research in GastroIntestinal Disorders, KU Leuven, Leuven, Belgium
Background/Purpose: Fibrosis is a key feature of systemic sclerosis, a devastating disease that is not well understood. The role of epigenetic factors in the pathophysiology…
Abstract Number: 115 • 2018 ACR/ARHP Annual Meeting
CTLA4-Ig/CD86 Interaction on Cultered Human Fibrocytes and Fibroblasts from Systemic Sclerosis Patients
Maurizio Cutolo¹, Paola Montagna², Stefano Soldano¹, Amelia Chiara Trombetta³, Barbara Ruaro⁴, Paola Contini⁵, Sabrina Paolino⁶, Carmen Pizzorni⁴, Elisa Alessandri⁴, Massimo Patanè¹, Alberto Sulli⁴, Stefano Scabini⁷, Emanuela Stratta⁷ and Renata Brizzolara¹, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Polyclinic San Martino Hospital, Genova, Italy, Genoa, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS Polyclinic San Martino, University of Genoa, Genova, Italy, ³Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS Polyclinic San Martino, University of Genoa, Genoa, Italy, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ⁵Division of Clinical Immunology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino, Genova, Italy, Genova, Italy, ⁶Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy, Genova, Italy, ⁷Oncologic Surgery, Department of Surgery, IRCCS Polyclinic San Martino, Genova, Italy, Genoa, Italy
Background/Purpose: CTLA4-Ig interacts with the cell surface costimulatory molecule CD86 and can downregulate the target cell activation [1]. Circulating fibrocytes (CFs) express markers of both…
Abstract Number: 119 • 2018 ACR/ARHP Annual Meeting
Targeting Dysregulated CD38/NAD+ Homeostasis Mitigates Multiple Organ Fibrosis
Bo Shi¹, Wenxia Wang², Swati Bhattacharyya¹, Benjamin Korman³, Roberta Goncalves Marangoni¹, David Camp⁴, Paul Cheresh⁵, Guilherme de Oliveira⁶, Eduardo Chini⁷ and John Varga¹, ¹Northwestern University, Chicago, IL, ²Feinberg School of Medicine, Northwestern University, Chicago, IL, ³Department of Rheumatology, Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ⁴Division of Pulmonary and Critical Care, Northwestern University, Chicago, IL, ⁵Northwestern University, CHICAGO, IL, ⁶Mayo Clinic of Medicine, Rochester, MN, ⁷Kogod Center on Aging, Mayo Clinic, Rochester, MN
Background/Purpose: Persistent myofibroblast activation underlies unresolving multi-organ fibrosis in systemic sclerosis (SSc). We had shown that fibrosis is associated with reduced expression of NAD-dependent sirtuins…
Abstract Number: 128 • 2018 ACR/ARHP Annual Meeting
Inhibition of Prolyl-tRNA Synthetase As a Novel Therapeutic Target for Systemic Sclerosis
Caroline H. Lee¹, Seong-Jin Yoon¹, Minjae Cho¹, Joon Seok Park², Yena Kim³, Ji Hyeon Ju⁴, Da-Jeong Bae⁵, Choon-Sik Park⁵, Jong Hyun Kim⁶, Sunghoon Kim⁶ and Bongyong Lee¹, ¹Daewoong Pharmaceuticals, Seoul, Korea, Republic of (South), ²Daewoong pharmaceutical, Seoul, Korea, Republic of (South), ³Catholic iPSC Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South), ⁴Division of Rheumatology, Department of Internal Medicine,, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South), ⁵Division of Allergy and Respiratory Medicine, Soonchunhyang University Bucheon Hospital, Seoul, Korea, Republic of (South), ⁶Medicinal Bioconvergence Research Center, Seoul National University, Seoul, Korea, Republic of (South)
Background/Purpose: Prolyl-tRNA synthetase (PRS), a member of aminoacyl tRNA synthetases (ARS), is an enzyme that conjugates amino acid proline to its tRNA to generate prolyl-tRNA…
Abstract Number: 1023 • 2018 ACR/ARHP Annual Meeting
Plasmacytoid Dendritic Cells That Infiltrate the Lungs Produce Profibrotic Cytokines and Chemokines in Bleomycin-Induced Model of Systemic Sclerosis
Isela Valera¹ and Ram R. Singh², ¹Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, UCLA, Los Angeles, CA, ²UCLA, Los Angeles, CA
Background/Purpose: In bleomycin-induced model of systemic fibrosis and patients with systemic sclerosis, plasmacytoid DC (pDC) are unaffected or reduced systemically (spleen/peripheral blood) but they increase…
Abstract Number: 1899 • 2018 ACR/ARHP Annual Meeting
Down-Regulation of RNA Processing Protein CFIm25 Amplifies Skin Fibrosis By up-Regulating Pro-Fibrotic Transcripts/Proteins in Systemic Sclerosis
Tingting Mills¹, Junsuk Ko¹, Jingjing Huang¹, Minghua Wu², Ningyuan Chen¹, Leng Han¹, Yu Xiang¹, Maureen D. Mayes³, Eric Wagner⁴, Michael Blackburn¹ and Shervin Assassi², ¹Department of Biochemistry & Molecular Biology, University of Texas Health Science Center at Houston, Houston, TX, ²Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ³Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁴Department of Biochemistry & Molecular Biology, The University of Texas Medical Branch at Galveston, Galveston, TX
Background/Purpose: Persistent myofibroblast activation and associated excessive extracellular matrix protein deposition are hallmarks of systemic sclerosis (SSc). However, the mechanisms that account for this excessive fibrotic response remain…
Abstract Number: 1901 • 2018 ACR/ARHP Annual Meeting
Reduced SPAG17 Expression Links Dysfunctional Cilia, Morphogen Signaling Activation and Multiple Organ Fibrosis: Novel Target for Systemic Sclerosis
Paulene Sapao¹, Bo Shi², Elisha D.O. Roberson³, John Atkinson⁴, Jerome Strauss¹, Maria Teves¹ and John Varga², ¹Virginia Commonwealth University, Richmond, VA, ²Northwestern University, Chicago, IL, ³Depts. of Medicine and Genetics, Division of Rheumatology, Washington University, St. Louis, MO, ⁴Medicine/Rheumatology, Washington University School of Medicine, St. Louis, MO
Background/Purpose: Persistent myofibroblast activation driving progressive fibrosis is the defining hallmark of systemic sclerosis (SSc). Uniquely, fibrosis in SSc affects the skin, heart, lungs and…
Abstract Number: 724 • 2017 ACR/ARHP Annual Meeting
Antibodies Against the Chemokine Receptors CXCR3 and CXCR4 Predict Progressive Lung Fibrosis in Systemic Sclerosis (SSc)
Gabriela Riemekasten¹, Elise Siegert² and Harald Heidecke³, ¹Department of Rheumatology, Universitatsklinikum Schleswig-Holstein, Lubeck, Germany, ²Rheumatology and Clinical Immunology, University Hospital Charité, Berlin, Germany, ³CellTrend GmbH Luckenwalde, Luckenwalde, Germany
Background/Purpose: Chemokine receptors CXCR3 and CXCR4 are involved in immune cell migration and in the pathogenesis of inflammatory fibrosis, a key feature of systemic sclerosis…
Abstract Number: 760 • 2017 ACR/ARHP Annual Meeting
Antisense Long Noncoding RNA HAND2-AS1 and OTUD6B-AS1 Have Important Roles in the Pathogenesis of Systemic Sclerosis
Miki Takata¹, Elena Pachera¹, Anastasiia Kozlova¹, Astrid Jüngel¹, Tobias Messemaker², Jeska de Vries-Bouwstra², Tom W.J. Huizinga³, Fina Kurreeman² and Oliver Distler⁴, ¹Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, Zurich, Switzerland, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, Leiden, Netherlands, ³Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ⁴Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Long noncoding RNAs (lncRNAs) represent a class of transcripts longer than 200 nucleotides that are not translated into proteins. In recent years, antisense (AS)…
Abstract Number: 1927 • 2017 ACR/ARHP Annual Meeting
Anti-Fibrotic Mechanisms of Endostatin-Derived Peptide Are the Result of Reduction in Pro-Fibrotic Mediators and Promotion of Extracellular Matrix Degradation
Tomoya Watanabe¹, Tetsuya Nishimoto², Takahisa Takihara³, Logan Mlakar⁴, Yunyun Su⁵ and Carol A. Feghali-Bostwick⁶, ¹Rheumatology, Medical University of South Carolina, Charleston, SC, ²Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, ³Division of Pulmonary Medicine, Tokai University School of Medicine, Isehara, Japan, ⁴Medical University of South Carolina, Charleston, SC, ⁵Medicine, Division of Rheumatology and Immunology, Medical University of South Carolina, charleston, SC, ⁶Division of Rheumatology and Immunology, Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, United States, Charleston, SC
Background/Purpose: Fibrotic disorders such as systemic sclerosis (SSc) result in end-stage organ failure and loss of function, consequently causing high morbidity and mortality. We recently…
Abstract Number: 2688 • 2017 ACR/ARHP Annual Meeting
Collagen Metabolite Biomarker Levels Are Associated with the Amount of Fibrosis in Internal Organs in Systemic Sclerosis Patients
Anne Sofie Siebuhr¹, Satoshi Kubo², Pernille Juhl³, K Nakano⁴, S Nakayamada⁵, Morten Karsdal⁶, Anne-C. Bay-Jensen⁷ and Yoshiya Tanaka⁸, ¹the first department of internal medicine, University of occupational and environmental health, Fukuoka, Japan, ²The first department of internal medicine, University of Occupational en environmental Health, Fukuoka, Japan, ³Nordic Bioscience, Herlev, Denmark, ⁴the first department of internal medicin, University of occupational and environmental health, fukuoka, Japan, ⁵The first department of internal medicine, University of Occupational and environmental Health, fukuoka, Japan, ⁶Biomarkers and Reseacrh, Nordic Bioscience, Herlev, Denmark, ⁷Biomarkers and Reseach, Nordic Bioscience, Herlev, Denmark, ⁸The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: Biomarkers that can monitor the fibrotic burden will aid in trial enrichment and personalized health care in SSc. SSc is associated with internal organ…
Abstract Number: 819 • 2016 ACR/ARHP Annual Meeting
Impaired Adiponectin Signaling in SSc Contributes to Myofibroblast Differentiation and Organ Fibrosis
Roberta Goncalves Marangoni¹, Benjamin Korman², Feng Fang¹, Monique Hinchcliff¹, Laszlo Otvos³, Philipp E. Scherer⁴, Warren Tourtellotte⁵ and John Varga⁶, ¹Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ²Department of Rheumatology, Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ³Temple University, Philadelphia, PA, ⁴University of Texas Southwestern Medical Center, Dallas, TX, ⁵Department of Pathology, Ward, Northwestern University, Chicago, IL, ⁶Rheumatology and Dermatology, Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL
Background/Purpose: In systemic sclerosis (SSc) patients, skin fibrosis is accompanied by involution of dermal white adipose tissue (dWAT), a prominent source of adiponectin (APN). We…
Abstract Number: 1857 • 2016 ACR/ARHP Annual Meeting
A Novel Highly Selective 5-Hydroxytryptamine 2B (5-HT2B) Receptor Antagonist Ameliorating Fibrosis in Preclinical Models of Systemic Sclerosis
Christina Wenglén¹, Lars Pettersson², Helena Arozenius² and Gunilla Ekström¹, ¹R&D, AnaMar AB, Lund, Sweden, ²AnaMar AB, Lund, Sweden
Background/Purpose: Methods: Results: Conclusion: The results demonstrate that the 5-HT2B receptor antagonist AM1125 prevents pro-fibrotic events in human dermal fibroblasts and attenuates…
Abstract Number: 2070 • 2016 ACR/ARHP Annual Meeting
Long Noncoding RNA H19X Is a Master Regulator of Extracellular Matrix Production in Systemic Sclerosis and Other Fibrotic Disease
Elena Pachera¹, Shervin Assassi², Gloria Salazar², Mojca Frank Bertoncelj¹, Rucsandra Dobrota¹, Matthias Brock³, Fina Kurreeman⁴, Jeska K. de Vries-Bouwstra⁴, Tobias Messemaker⁴, Carol Feghali-Bostwick⁵, Jeorg HW Distler⁶, Gabriela Kania¹ and Oliver Distler¹, ¹Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Department of Internal Medicine - Rheumatology, University of Texas-McGovern Medical School, Houston, TX, ³Department of Pulmonology, University Hospital Zurich, Zurich, Switzerland, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, ⁶Internal Medicine 3, University of Erlangen, Erlangen, Germany
Background/Purpose: Long noncoding RNAs (lncRNAs) are an emerging class of large noncoding transcripts involved in the regulation of gene expression in health and disease. We…
Abstract Number: 3173 • 2016 ACR/ARHP Annual Meeting
Pan-PPAR Agonist IVA337 Is Effective in the Prevention of Experimental Lung Fibrosis and Related Pulmonary Hypertension
Jerome Avouac¹, Irena Konstantinova², Christophe Guignabert³, Sonia Pezet⁴, Anne Cauvet⁵, Jeremy Sadoine⁶, Thomas Guilbert⁴, Jean-Michel Luccarini⁷, Jean-Louis Junien⁷, Pierre Broqua⁷ and Yannick Allanore⁸, ¹Rheumatology A department and INSERM U1016, Paris Descartes University, Cochin Hospital, Paris, France, ²Inventiva, Daix, France, ³Inserm UMR_S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France, ⁴Institut Cochin, INSERM U1016, Paris, France, ⁵INSERM U1016, Paris Descartes University, Cochin Hospital, Paris, France, ⁶Equipe d’Accueil (EA) 2496 Pathologie, Imagerie et Biothérapies Orofaciales, Faculty of Odontology, Paris Descartes University, Montrouge, France, ⁷Inventiva, DAIX, France, ⁸Rheumatology, Paris Descartes University, Paris, France
Background/Purpose: Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors known to modulate fibrosis. The pan-PPAR agonist IVA337 recently demonstrated efficacy in prevention and treatment of experimental…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].